CUROGEN

CUROGEN is a leading biotechnology research company dedicated to addressing unmet medical needs in autoimmune disease. With a focus on innovation, CUROGEN is developing therapeutics that effectively regulate disease targets. These therapeutics are being developed in the forms of both small molecule compounds and soluble fusion proteins, showcasing a versatile approach to treatment. CUROGEN's commitment to research and development aims to bring next-generation solutions to patients worldwide. The primary address of CUROGEN is Magokjungang-ro 172, Gangseo-gu, Bio Innovation Park Building 5F, Seoul, Seoul 07789, KR, with an additional location at Seobu-ro 2066, Jangan-gu, Corporate Collaboration Center, #85413, Suwon, Gyeonggi-do 16419, KR.

CUROGEN is at the forefront of biotechnology, striving to create groundbreaking treatments for autoimmune conditions. The company's research initiatives are geared towards identifying and modulating key disease targets, ensuring the development of highly effective and targeted therapies. CUROGEN's work is driven by a vision to improve patient outcomes and enhance the quality of life for individuals affected by autoimmune disorders.

CUROGEN continues to expand its research capabilities and therapeutic pipeline. The company remains dedicated to advancing scientific knowledge and translating discoveries into innovative medical solutions. We invite the management team at CUROGEN to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.